|
| 37738504 | Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine. | Annu Rev Pharmacol Toxicol | 2024 |
| 37994196 | Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. | Am J Hematol | 2024 |
| 36315007 | Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. | Blood Adv | 2023 |
| 37509251 | Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia. | Cancers (Basel) | 2023 |
| 37685882 | Cytogenetically Cryptic Acute Promyelocytic Leukemia: A Diagnostic Challenge. | Int J Mol Sci | 2023 |
| 37815132 | The FLT3<sup>N701K</sup> mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. | Am J Hematol | 2023 |
| 37263072 | Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. | Leuk Res | 2023 |
| 36441905 | Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. | Blood Adv | 2023 |
| 35896960 | Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML. | Clin Proteomics | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 34171263 | The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. | Cancer Cell | 2021 |
| 33901720 | Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse. | Transplant Cell Ther | 2021 |
| 33780043 | A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance. | Am J Hematol | 2021 |
| 33939107 | IDH Inhibitors in AML-Promise and Pitfalls. | Curr Hematol Malig Rep | 2021 |
| 32366937 | ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. | Leukemia | 2020 |
| 32021432 | Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. | Cancer Manag Res | 2020 |
| 33106665 | Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. | Nat Med | 2020 |
| 32315394 | Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. | Blood | 2020 |
| 30720426 | FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. | Elife | 2019 |
| 31830279 | Reducing acetyl-CoA enhances BET inhibition. | Blood | 2019 |
| 30924767 | Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. | Elife | 2019 |
| 30836091 | Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged â¿¥70 years. | Hematol Oncol Stem Cell Ther | 2019 |
| 31145495 | The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. | Am J Hematol | 2019 |
| 30760466 | Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. | Blood Adv | 2019 |
| 29165010 | DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. | Leuk Lymphoma | 2018 |
| 29892546 | Acute promyelocytic leukemia presenting with features of metastatic osseous disease. | Leuk Res Rep | 2018 |
| 29860938 | Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. | N Engl J Med | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 28013106 | CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. | Leuk Res | 2017 |
| 28355571 | Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. | Cell Rep | 2017 |
| 28784769 | Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. | Proc Natl Acad Sci U S A | 2017 |
| 28719608 | Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. | PLoS One | 2017 |
| 26095727 | Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance. | Br J Haematol | 2016 |
| 26573090 | Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. | Am J Hematol | 2016 |
| 27671675 | FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | Cancer Res | 2016 |
| 27582059 | Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Sci Transl Med | 2016 |
| 27124934 | Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. | Am J Clin Pathol | 2016 |
| 27036514 | Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent. | J Hematol Oncol | 2016 |
| 25432174 | Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. | Cancer Res | 2015 |
| 26075913 | TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. | PLoS One | 2015 |
| 24408322 | Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. | Blood | 2014 |
| 25628989 | Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. | Leuk Res Rep | 2014 |
| 22094585 | Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. | Leukemia | 2012 |
| 20529804 | How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. | Clin Lymphoma Myeloma Leuk | 2010 |
| 16085745 | Do weekend plan standard forms improve communication and influence quality of patient care? | Postgrad Med J | 2005 |
| 12783855 | Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. | Genes Dev | 2003 |
| 10706894 | Evaluation of human diacylglycerol kinase(iota), DGKI, a homolog of Drosophila rdgA, in inherited retinopathy mapping to 7q. | Mol Vis | 2000 |
| 9809998 | The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli. | Cancer Res | 1998 |
| 9830018 | The cloning and characterization of a novel human diacylglycerol kinase, DGKiota. | J Biol Chem | 1998 |
| 9598324 | Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4). | Genomics | 1998 |